Abbott’s Absorb GT1 Bioresorbable Scaffold Gets FDA Panel Date
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories' Absorb GT1 Bioresorbable Vascular Scaffold System will soon be the first fully bioresorbable coronary scaffold to undergo FDA panel review. During a two-day Circulatory Systems Devices panel meeting in March, the panel will assess Absorb as well as Angel Medical System’s Angelmed Guardian System, an implantable monitor made to alert patients to coronary ischemia.
You may also be interested in...
Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear
Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.